DEVONIAN HEALTH GROUP INC (GSD.CA) Stock Price, Forecast & Analysis
Canada • TSX Venture Exchange • TSX-V:GSD • CA2518348008
GSD.CA Key Statistics, Chart & Performance
The current stock price of GSD.CA is 10 CAD. In the past month the price increased by 5455.56%. In the past year, price increased by 6150%.
GSD.CA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to GSD.CA. When comparing the yearly performance of all stocks, GSD.CA is one of the better performing stocks in the market, outperforming 100% of all stocks.
GSD.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GSD.CA. GSD.CA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
GSD.CA Financial Highlights
Over the last trailing twelve months GSD.CA reported a non-GAAP Earnings per Share(EPS) of -2.66. The EPS decreased by -22454.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.73% | ||
| ROE | -72.55% | ||
| Debt/Equity | 0.01 |
GSD.CA Forecast & Estimates
GSD.CA Ownership
GSD.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| BHC | BAUSCH HEALTH COS INC | 1.39 | 2.978B | ||
| CRON | CRONOS GROUP INC | 36.59 | 1.378B | ||
| TLRY | TILRAY BRANDS INC | N/A | 1.203B | ||
| DHT-UN | DRI HEALTHCARE TRUST | 7.14 | 898.293M | ||
| GUD | KNIGHT THERAPEUTICS INC | 124.02 | 583.825M | ||
| WEED | CANOPY GROWTH CORP | N/A | 556.375M | ||
| NGEN | NERVGEN PHARMA CORP | N/A | 393.546M | ||
| CPH | CIPHER PHARMACEUTICALS INC | 27.1 | 365.328M | ||
| TSND | TERRASCEND CORP | N/A | 338.79M |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the TSX Venture Exchange Exchange | Find more ETFs on the Canadian exchanges | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About GSD.CA
Company Profile
Devonian Health Group, Inc. is a pharmaceutical company, which engages in the development of botanical drugs. The company is headquartered in Montmagny, Quebec and currently employs 8 full-time employees. The company went IPO on 2014-09-09. The company specializes in the development of drugs for various autoimmune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. The company is developing prescription drugs for the treatment of inflammatory autoimmune diseases, including but not limited to, ulcerative colitis and atopic dermatitis. The company is also involved in the development of cosmeceutical products, leveraging the same proprietary approach employed with their pharmaceutical offerings. Its flagship product, Thykamine, is a pharmaceutical product issued from its SUPREX platform, for the prevention and treatment of health problems related to inflammation and oxidative stress, including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune diseases. Its cosmeceutical products include R-Spinasome and Purgenesis. Its subsidiary, Altius Healthcare Inc., sells prescription pharmaceutical products.
Company Info
DEVONIAN HEALTH GROUP INC
360 rue des Entrepreneurs
Montmagny QUEBEC G5V 4T1 CA
CEO: Andre P. Boulet
Employees: 7
Phone: 15142487509
DEVONIAN HEALTH GROUP INC / GSD.CA FAQ
What does GSD do?
Devonian Health Group, Inc. is a pharmaceutical company, which engages in the development of botanical drugs. The company is headquartered in Montmagny, Quebec and currently employs 8 full-time employees. The company went IPO on 2014-09-09. The company specializes in the development of drugs for various autoimmune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. The company is developing prescription drugs for the treatment of inflammatory autoimmune diseases, including but not limited to, ulcerative colitis and atopic dermatitis. The company is also involved in the development of cosmeceutical products, leveraging the same proprietary approach employed with their pharmaceutical offerings. Its flagship product, Thykamine, is a pharmaceutical product issued from its SUPREX platform, for the prevention and treatment of health problems related to inflammation and oxidative stress, including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune diseases. Its cosmeceutical products include R-Spinasome and Purgenesis. Its subsidiary, Altius Healthcare Inc., sells prescription pharmaceutical products.
Can you provide the latest stock price for DEVONIAN HEALTH GROUP INC?
The current stock price of GSD.CA is 10 CAD.
What is the dividend status of DEVONIAN HEALTH GROUP INC?
GSD.CA does not pay a dividend.
What is the ChartMill rating of DEVONIAN HEALTH GROUP INC stock?
GSD.CA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of GSD stock?
DEVONIAN HEALTH GROUP INC (GSD.CA) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the ownership details for GSD stock?
You can find the ownership structure of DEVONIAN HEALTH GROUP INC (GSD.CA) on the Ownership tab.